JPH0344330A - External preparation containing zizania latifolia o.stapf and relative thereof - Google Patents
External preparation containing zizania latifolia o.stapf and relative thereofInfo
- Publication number
- JPH0344330A JPH0344330A JP1178874A JP17887489A JPH0344330A JP H0344330 A JPH0344330 A JP H0344330A JP 1178874 A JP1178874 A JP 1178874A JP 17887489 A JP17887489 A JP 17887489A JP H0344330 A JPH0344330 A JP H0344330A
- Authority
- JP
- Japan
- Prior art keywords
- stapf
- external preparation
- genus
- preparation containing
- bacillus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 244000085595 Zizania latifolia Species 0.000 title claims abstract 9
- 235000004259 Zizania latifolia Nutrition 0.000 title claims abstract 9
- 241000894006 Bacteria Species 0.000 claims abstract description 21
- 108090000790 Enzymes Proteins 0.000 claims abstract description 13
- 102000004190 Enzymes Human genes 0.000 claims abstract description 13
- 241000193830 Bacillus <bacterium> Species 0.000 claims abstract description 12
- 108010059820 Polygalacturonase Proteins 0.000 claims abstract description 5
- 239000004382 Amylase Substances 0.000 claims abstract description 4
- 108010065511 Amylases Proteins 0.000 claims abstract description 4
- 102000013142 Amylases Human genes 0.000 claims abstract description 4
- 235000019418 amylase Nutrition 0.000 claims abstract description 4
- 108090001060 Lipase Proteins 0.000 claims abstract description 3
- 239000004367 Lipase Substances 0.000 claims abstract description 3
- 102000004882 Lipase Human genes 0.000 claims abstract description 3
- 101000763602 Manilkara zapota Thaumatin-like protein 1 Proteins 0.000 claims abstract description 3
- 101000763586 Manilkara zapota Thaumatin-like protein 1a Proteins 0.000 claims abstract description 3
- 101000966653 Musa acuminata Glucan endo-1,3-beta-glucosidase Proteins 0.000 claims abstract description 3
- 241000194105 Paenibacillus polymyxa Species 0.000 claims abstract description 3
- 108091005804 Peptidases Proteins 0.000 claims abstract description 3
- 239000004365 Protease Substances 0.000 claims abstract description 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims abstract description 3
- 235000019421 lipase Nutrition 0.000 claims abstract description 3
- 238000012258 culturing Methods 0.000 claims abstract 3
- 108010093305 exopolygalacturonase Proteins 0.000 claims abstract 2
- 230000000699 topical effect Effects 0.000 claims description 3
- 241000193755 Bacillus cereus Species 0.000 claims description 2
- 230000000813 microbial effect Effects 0.000 claims description 2
- 238000010521 absorption reaction Methods 0.000 abstract description 5
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 5
- 239000000203 mixture Substances 0.000 abstract description 5
- 239000000126 substance Substances 0.000 abstract description 5
- 241000193744 Bacillus amyloliquefaciens Species 0.000 abstract description 2
- 241000194107 Bacillus megaterium Species 0.000 abstract description 2
- 241000196324 Embryophyta Species 0.000 abstract description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 abstract 1
- 240000001817 Cereus hexagonus Species 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 8
- 229940079593 drug Drugs 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 4
- -1 vectinase Proteins 0.000 description 4
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 3
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 239000008311 hydrophilic ointment Substances 0.000 description 3
- 229920003049 isoprene rubber Polymers 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000004745 nonwoven fabric Substances 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 235000011069 sorbitan monooleate Nutrition 0.000 description 3
- 229940035049 sorbitan monooleate Drugs 0.000 description 3
- 239000001593 sorbitan monooleate Substances 0.000 description 3
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 2
- 241001660259 Cereus <cactus> Species 0.000 description 2
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 description 2
- 241000746966 Zizania Species 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000010200 folin Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 229940041616 menthol Drugs 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 229960001047 methyl salicylate Drugs 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 239000011505 plaster Substances 0.000 description 2
- 229920002492 poly(sulfone) Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000209504 Poaceae Species 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- SCJNCDSAIRBRIA-DOFZRALJSA-N arachidonyl-2'-chloroethylamide Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCCl SCJNCDSAIRBRIA-DOFZRALJSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940124641 pain reliever Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
【発明の詳細な説明】
［産業上の利用分野１
本発明は、？Ｄモ（Ｚｉｚａｎｉａ Ｉａｔｉｆｏｌｉ
ａ Ｏ，５ｔａｐｆ）及びその近縁類を培地とし、Ｂａ
ｃｉｌｌｕｓ属の細菌を培養した物を含有する外用剤に
関する。[Detailed Description of the Invention] [Industrial Application Field 1 What is the scope of the present invention? Dmo (Zizania Iatifoli)
aO, 5tapf) and its relatives as a medium, Ba
The present invention relates to an external preparation containing cultured bacteria of the genus Cillus.
［従来技術１
近年、外用医薬品、医薬部外品等の治療剤の発展はめざ
ましいものがあるが、合成医薬品が大半であり種々の副
作用が問題になっているのが現状である。[Prior Art 1] In recent years, therapeutic agents such as external drugs and quasi-drugs have made remarkable progress, but at present most of them are synthetic drugs, and various side effects have become a problem.
［発明が解決しようとする問題点１
従来の外用医薬品で、心臓痛論や消炎鎮痛剤を各種膏体
に配合した物の場合は、経皮吸収不充分であったり、持
続性に欠ける問題があり、＠創始療剤の内、消炎酵素剤
の場合、不活化を起こしやすく、経時変化の為、効果の
低下をきたすという問題があった。[Problem to be solved by the invention 1] Conventional external medicines containing various types of plasters containing cardiac pain relievers and anti-inflammatory analgesics have problems such as insufficient transdermal absorption and lack of sustainability. Yes, among the primary therapeutic agents, anti-inflammatory enzyme agents have the problem of being easily inactivated and decreasing in effectiveness due to changes over time.
従って、本発明の目的は、経皮吸収が良好で、持続性の
ある外用医薬品及び不活化しにくい消炎酵素外用治療薬
を提供することである。Therefore, an object of the present invention is to provide a topical drug that has good transdermal absorption and a long-lasting effect, and a topical anti-inflammatory enzyme therapeutic drug that is not easily inactivated.
［問題点を解決する為の手段］
かかる問題を解決する為、本発明は、マコモ（２ｉｚａ
ｎｉａ Ｉａｔｉｆｏｌｉａ Ｏ，５ｔａｐｆ）及びそ
の近縁類を培地とし、Ｂａｃｉ ｌ Ｉｕｓ属の細菌を
培養した物を含有することを特徴とする外用剤を提案す
るものである本発明による外用剤は、７１モ（２ｉｚａ
ｎｉａ Ｉａｔｉ−ｆｏｌｉａ Ｏ，５ｔａｐｆ）及び
その近縁類を培地とし、Ｂａｃ −ｉ Ｉ Ｉｕｓ属の
細菌を培養した物を含有することが必須である。[Means for Solving the Problems] In order to solve the problems, the present invention utilizes Makomo (2iza
The external preparation according to the present invention is characterized in that it contains cultured bacteria of the genus Bacillus using a culture medium of Nia Iatifolia O, 5 tapf) and its relatives. (2iza
It is essential that the culture medium contains bacteria of the genus Bac-i I Ius, using Bac-i Iati-folia O, 5 tapf) and its relatives as a medium.
本発明に用いるマコモ（Ｚｉｚａｎｉａ Ｉａｔｉｆｏ
ｌｉａ ００Ｓｔａｐｒ）及びその近縁類を培地とし、
ＢａｃｉｒＩｕｓ属の細菌を培養した物には、イネ科の
植物マ］モ（Ｚｉ−Ｚａｎｉａ Ｉａｔｉｆｏｌｉａ
ｏ、５ｔａｐｒ）及びその近縁類に、８−ａｃｉｌｌｕ
ｓ属の細菌を作用させ、５０〜９５℃の比較的高温で培
養した物を、適当な大きさに細断した物や微粉末にした
物を用いる。必要に応じて、水製エキス、流エキス、Ｂ
ａｃｉｌｌｕｓ属生菌単体、酵素、脱酵素分画、脱細菌
分画などを用いることができる。Zizania Iatifo used in the present invention
lia 00 Stapr) and its relatives as a medium,
Cultured bacteria of the genus Bacirius include Zi-Zania Iatifolia, a plant of the Poaceae family.
o, 5tapr) and its relatives, 8-acillu
A material that has been cultured at a relatively high temperature of 50 to 95° C. with bacteria of the genus S and then shredded into appropriate sizes or made into a fine powder is used. If necessary, water extract, liquid extract, B
Acillus genus live bacteria alone, enzymes, deenzyme fractions, debacteria fractions, and the like can be used.
本発明に用いるＢａｃｉｌｌｕｓ属の細菌は、内生芽胞
をつくる桿菌及び球菌で、ＢａＣｉ Ｉ Ｉ ａＣｅａ
ｅ科の物であれば有用な物が多いが、特に、Ｂａｃｉｌ
ｌｕｓ ５ｕｂｔ−ｉｌｉｓ、 Ｂａｃｉｌｌｕｓ ５
ｕｂｔｉｌｉｓ ０Ｎ−１（工業技術院微生物技術研究
所寄託．ＦＥＲＭ−ＰＮｏｄ６０８） 、Ｂａｃｉｌｌ
ｕｓｃｅｒｅｕｓ、 Ｂａｃｉｌｌｕｓ ｍｅｇａｔｅ
ｒｉｕｍ 、 Ｂａｃｉｌｌｕｓ ｐｏｌｙ−ｍｙｘａ
、 Ｂａｃｉｌｌｕｓ Ａｍｙｌｏｌｉｑｕｅｆａｃｉ
ｅｎｓなどが好ましい。The bacteria of the genus Bacillus used in the present invention are bacilli and cocci that produce endospores, and include BaCi II aCea.
Many members of the e family are useful, but in particular, Bacillus
lus 5ubt-ilis, Bacillus 5
ubtilis 0N-1 (Deposited with the Institute of Microbial Technology, Agency of Industrial Science and Technology. FERM-PNod608), Bacill
uscereus, Bacillus megate
rium, Bacillus poly-myxa
, Bacillus Amyloliquefaci
ens etc. are preferable.
また、酵素を用いる場合は、ゲルパーミッションクロマ
トグラフィーや膜分離、塩析、溶媒分離法などで精製し
た物が好ましいが、透析処理程度の粗製分画でも使用可
能である。酵素は、プロテアーゼ、ポリガラクチュロナ
ーゼ、リパーゼ、ベクチナービ、β−１，３−グルカナ
ーゼ、アミラーゼムどであるが、特に、プロプアーゼと
アミラーゼが有用である。In addition, when using an enzyme, it is preferable to use one purified by gel permeation chromatography, membrane separation, salting out, solvent separation, etc., but crude fractions obtained by dialysis treatment can also be used. Enzymes include protease, polygalacturonase, lipase, vectinase, β-1,3-glucanase, amylase, etc., and particularly useful are propase and amylase.
［作用・効果］
本発明の外用剤は、経皮吸収を促進し、消炎作用を持つ
物であり、化学合成医薬品、ホルモン剤等にみられる副
作用のないものである。[Action/Effect] The external preparation of the present invention promotes transdermal absorption, has an anti-inflammatory effect, and does not have the side effects seen in chemically synthesized drugs, hormone preparations, and the like.
実施例１（軟膏）
マコモ乾燥物ｉｏｏ ｇとＢａｃｉｌｌｕｓ ５ｕｂｔ
ｉｌｉｓと８−ａｃｉｌｌｕｓ ｃｅｒｅｕｓを用い７
５℃で培養した物を、日本薬局方親水軟膏と均一に混合
し、仝墨をｉ ０００ ｇとした物。Example 1 (Ointment) Dry Makomo ioo g and Bacillus 5ubt
7 using S. ilis and 8-acillus cereus.
The product cultured at 5°C was uniformly mixed with hydrophilic ointment of the Japanese Pharmacopoeia, and the amount was made into i 000 g.
比較例１
日本薬局方親水軟膏 １０００ｇ
比較例２
吉草酸ベタメタシン１．２ｇを、日本薬局方親水軟膏と
均一に混合し、全品をｉ ｏｏｏ ｇとした物。Comparative Example 1 Japanese Pharmacopoeia Hydrophilic Ointment 1000g Comparative Example 2 1.2 g of betamethacin valerate was uniformly mixed with the Japanese Pharmacopoeia Hydrophilic Ointment, and the entire product was made into i ooo g.
実施例２（プラスター剤）
イソプレンゴム １００９０ジン
１００９日本薬日本論動パラフィン
５００ｇソルビタンモノオレート ５０
ｇポリオキシエチレン〈１５モル）オレイルエーテル
５０ｇ以上を混合した
物と、マコモ乾燥物２００ ｇと８−ａｃｉｌｌｕｓ
５ｕｂｔｉｌｉｓ１Ｂａｃｉｌｌｕｓ ｃｅｒｅｕｓ
、 Ｂａｃ＋ｌ１ｕ−３ＡＩＩＩＶＩＯＩ １ｑｕｅｆ
ａｃｉｅｎｓを用い８０℃で培養した物を水１１て抽出
し、その液を１０μ机の膜モジュールでろ過し、そのろ
液をポリスルフォン膜を用いて分子量１０００以下の物
質を除去した物仝＠（カゼイン−フォーリン法で測定し
た酵素単価として約２０万単位を含む。本分画には生菌
も含有される）とを７０℃に加熱しながら混和し、更に
水２００ ｇを加え強く乳化させる。これを温時、不織
布に１０μ卯の厚さに塗布し、離型紙を上から被せた物
。Example 2 (Plastering agent) Isoprene rubber 10090 Gin
1009 Nippon Yaku Nihon Rondo Paraffin 500g Sorbitan Monooleate 50
g Polyoxyethylene (15 mol) oleyl ether
A mixture of 50g or more, 200g of dried makomo and 8-acillus
5ubtilis1Bacillus cereus
, Bac+l1u-3AIIIVIOI 1quef
aciens was cultured at 80°C and extracted with water, the liquid was filtered through a 10μ membrane module, and the filtrate was filtered using a polysulfone membrane to remove substances with a molecular weight of 1000 or less. This fraction contains approximately 200,000 units of enzyme unit as measured by the casein-folin method. This fraction also contains live bacteria) and is mixed while heating to 70°C, and further 200 g of water is added to strongly emulsify. This was applied to a nonwoven fabric to a thickness of 10 μm when warm, and a release paper was placed on top.
実施例３
イソプレンゴム ｉｏｏｇロジン
１００９日本薬局方流動パラフィン
３４０ｇソルビタンモノオレート ５０
ｇポリオキシエチレン（１５モル〉オレイルエーテル
５０ｇ！−メントー
ル ５０ｇｄ−カンフ７
５０ｇサリチル酸メチル
１００ｇｄ１−α−トコフェロール １０
ｇ以上を混合した物と、マコモ乾燥物２００９と８−ａ
ｃｉｌｌｕｓ ５ｕｂｔｉｌｉｓ１Ｂａｃｉｌｌｕｓ
ｃｅｒｅｕｓ 、 Ｂａｃｉｌｌｕ−ｓ Ａｍｙｌｏｌ
１ｑｕｅｆａｃｉｅｎｓを用い８０℃で培養した物を
水１ｆｌで抽出し、その液を１０ＬＩＴｒｔの膜モジュ
ールでろ過し、そのろ液をポリスルフォン膜を用いて分
子＠１０００以下の物質を除去した物仝＠（カゼイン−
フォーリン法で測定した酵素単価として約２０万単位を
含む。本分画には生菌は含有される）とを７０℃に加熱
しながら混和し、更に水２００９を加え強く乳化させる
。これを温時、不織布に１０μ扉の厚さに塗布し、離型
紙を上から被せた物。Example 3 Isoprene rubber ioog rosin
1009 Japanese Pharmacopoeia Liquid Paraffin 340g Sorbitan Monooleate 50
g Polyoxyethylene (15 mol) oleyl ether
50g! -Menthol 50gd-Kanfu 7
50g methyl salicylate
100gd1-α-tocopherol 10
A mixture of more than g and dried makomo 2009 and 8-a
cillus 5ubtilis1 Bacillus
cereus, Bacillus Amylol
1 quefaciens was cultured at 80°C and extracted with 1 fl of water, the liquid was filtered through a 10LITrt membrane module, and the filtrate was filtered using a polysulfone membrane to remove substances with molecules of less than 1000 molecules. Casein-
Contains approximately 200,000 units of enzyme unit price measured by the Folin method. (This fraction contains live bacteria) are mixed while heating to 70°C, and further water 2009 is added to strongly emulsify. This was applied to a non-woven fabric to a thickness of 10μ when heated, and a release paper was placed on top.
比較例３
イソプレンゴム ｉｏｏｇロジン
１００ｇ日本薬日本論動パラフィ
ン ３４０ ｇソルビタンモノオレート
５０ｇポリオキシエチレン（１５モル〉オレイルエーテ
ル ５０ｇ−メントー
ル ５０ｇｄ−カンフ？
５０ｇサリチル酸メチル
１００ｇｄ！−α−ト」フェロール
１０ｇ以上を７０℃に加熱しながら混和し、更に水２０
０９を加え強く乳化させる。これを温時、不織布に１０
μ机の厚さに塗布し、離型紙を上から被せた物。Comparative Example 3 Isoprene rubber ioog rosin
100g Nihon Yaku Nippon Rondo Paraffin 340g Sorbitan Monooleate
50g polyoxyethylene (15 moles) oleyl ether 50g - menthol 50gd - camphor?
50g methyl salicylate
100gd! −α−to” ferol
Mix 10g or more while heating to 70℃, and add 20g of water.
Add 09 and emulsify strongly. When heated, apply 10% to the non-woven fabric.
It is coated to the thickness of μ and covered with release paper.
実験例１
ラットの皮膚に８０番のサンドペーパーですり傷をつく
り、皮下にカラゲニンを注入した後、上記実施例及び比
較例で得られた各軟膏（プラスター剤）を０．１ｇ／Ｃ
ｌ１（φ２．５ｃｍ＞の量で塗布し、２４時間放置後、
浮腫の重量を求めた。Experimental Example 1 After making an abrasion on the skin of a rat with No. 80 sandpaper and injecting carrageenin subcutaneously, 0.1 g/C of each ointment (plaster agent) obtained in the above Examples and Comparative Examples was applied.
Apply an amount of l1 (φ2.5cm>) and leave it for 24 hours,
The weight of the edema was determined.
その結果は、以下の第−表に示す通りである。The results are shown in the table below.
第−表
実験例２
滲出液のあるヒト湿疹に対して、上記実施例及び比較例
で得られた各軟膏（プラスター剤）を、０．１９／Ｃｌ
１（φ２．５ｃｍ＞の量で塗布（貼布）し、１日２回交
換して１週間後、その状態を観察した。Table - Experimental Example 2 For human eczema with exudate, each ointment (plaster) obtained in the above Examples and Comparative Examples was applied at 0.19/Cl.
1 (φ2.5 cm>), and the condition was observed after 1 week after changing twice a day.
その結果は、以下の第二衣に示す通りである。The results are shown in the second section below.
第二衣
本発明の外用剤は、上記実験から明らかなように、優れ
た抗炎症作用と経皮吸収促進効果を示しかつ副作用ない
し毒性の低いものであり、外用剤として極めて優れたも
のである。Second Clothing As is clear from the above experiments, the external preparation of the present invention exhibits excellent anti-inflammatory effects and transdermal absorption promoting effects, and has low side effects and toxicity, making it extremely excellent as an external preparation. .
Claims (7)
Ｓｔａｐｆ）及びその近縁類を培地とし、Ｂａｃｉｌｌ
ｕｓ属の細菌を培養した物を含有する外用剤。(1) Makomo (Zizanialatifolia O.
Stapf) and its relatives as a medium,
An external preparation containing cultured bacteria of the genus Us.
Ｓｔａｐｆ）及びその近縁類を培地とし、Ｂａｃｉｌｌ
ｕｓ属の細菌を培養して得た酵素を含有する外用剤。(2) Makomo (Zizanialatifolia O.
Stapf) and its relatives as a medium,
An external preparation containing an enzyme obtained by culturing bacteria of the genus Us.
Ｓｔａｐｆ）及びその近縁類を培地とし、Ｂａｃｉｌｌ
ｕｓ属の細菌を培養して得た物から酵素を除いた分画を
含有する外用剤。(3) Makomo (Zizanialatifolia O.
Stapf) and its relatives as a medium,
An external preparation containing a fraction obtained by culturing bacteria of the genus U.S., with enzymes removed.
Ｓｔａｐｆ）及びその近縁類を培地とし、Ｂａｃｉｌｌ
ｕｓ属の細菌を培養して得た物から、Ｂａｃｉｌｌｕｓ
属の生菌を単離した物を含有する外用剤。(4) Makomo (Zizanialatifolia O.
Stapf) and its relatives as a medium,
Bacillus
A topical preparation containing isolated viable bacteria of the genus.
Ｓｔａｐｆ）及びその近縁類を培地とし、Ｂａｃｉｌｌ
ｕｓ属の細菌を培養して得た物から、Ｂａｃｉｌｌｕｓ
属の生菌を除いた物を含有する外用剤。(5) Makomo (Zizanialatifolia O.
Stapf) and its relatives as a medium,
Bacillus
External preparation containing viable bacteria of the genus.
ｓｕｂｔｉｌｉｓＢａｃｉｌｌｕｓｓｕｂｔｉｌｉｓＯ
Ｎ−１（工業技術院微生物技術研究所寄託．ＦＥＲＭ−
ＰＮｏ４６０８）、ＢａｃｉｌｌｕｓｃｅｒｅｕｓＢａ
ｃｉｌｌｕｓｍｅｇａｔｅｒｉｕｍ、Ｂａｃｉｌｌｕｓ
ｐｏｌｙｍｙｘａ、Ｂ−ａｃｉｌｌｕｓＡｍｙｌｏｌｉ
ｑｕｅｆａｃｉｅｎｓの中から選ばれた物の内、一種類
以上を含む物である特許請求の範囲第（１）項から第（
５）項に記載の外用剤。(6) Bacteria of the genus Bacillus are
subtilisBacillus subtilisO
N-1 (Deposited with the Institute of Microbial Technology, Agency of Industrial Science and Technology. FERM-
PNo. 4608), Bacillus cereus Ba
cillus megaterium, Bacillus
polymyxa, B-acillus Amyloli
Claims (1) to (1) include one or more types selected from quefaciens.
The external preparation described in section 5).
、ペクチナーゼ、β−１，３−グルカナーゼ、リパーゼ
、アミラーゼの内、一種類以上を含む特許請求の範囲第
（２）項に記載の外用剤。(7) The external preparation according to claim (2), wherein the enzyme contains one or more of protease, polygalacturonase, pectinase, β-1,3-glucanase, lipase, and amylase.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP1178874A JPH0344330A (en) | 1989-07-10 | 1989-07-10 | External preparation containing zizania latifolia o.stapf and relative thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP1178874A JPH0344330A (en) | 1989-07-10 | 1989-07-10 | External preparation containing zizania latifolia o.stapf and relative thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH0344330A true JPH0344330A (en) | 1991-02-26 |
Family
ID=16056206
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP1178874A Pending JPH0344330A (en) | 1989-07-10 | 1989-07-10 | External preparation containing zizania latifolia o.stapf and relative thereof |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH0344330A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009091286A (en) * | 2007-10-05 | 2009-04-30 | Nippon Menaade Keshohin Kk | Fermentation treated product of zizania latifolia |
-
1989
- 1989-07-10 JP JP1178874A patent/JPH0344330A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009091286A (en) * | 2007-10-05 | 2009-04-30 | Nippon Menaade Keshohin Kk | Fermentation treated product of zizania latifolia |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2255730T3 (en) | TOPICAL USE OF SPORTS OF PROBIOTIC BACLES TO PREVENT OR TREAT MICROBIAL INFECTIONS. | |
| EP1212093B1 (en) | Use of emu oil as a carrier for antifungal, antibacterial and antiviral medications | |
| DE3606265A1 (en) | POLYSACCHARID-BASED Wound Dressing As a Carrier Therapeutically Effective, Non-Immobilized Enzymes and with High Absorbency | |
| RU2106154C1 (en) | Wound dressing material | |
| RU2108079C1 (en) | Method for treating burn wounds | |
| AU740303B2 (en) | External preparations containing watercress extract | |
| KR960700766A (en) | Pharmaceutical composition consisting of sponge material in which ester derivative of hyaluronic acid is combined with other pharmaceutically effective substances | |
| KR20100079586A (en) | Composition for anti atopy-dermatitis containing cirsium japonicum var. ussuriense extract | |
| TW200803924A (en) | A sheet device comprising bio-cellulose for alleviating skin damage and relieving skin problem | |
| JPH0344330A (en) | External preparation containing zizania latifolia o.stapf and relative thereof | |
| JP2003517448A (en) | Enzymatic treatment and prevention of hypertrophic skin | |
| EP3666341B1 (en) | Topical formulation in form of a patch, a bandage or a plaster comprising probiotic bacteria, and use thereof in a method for treating or preventing skin disorders | |
| JP2022539518A (en) | Composition with antibacterial and re-epithelializing action containing probiotics | |
| RU2108078C1 (en) | Method for treating deep burn wounds | |
| AU2006201179B2 (en) | Use of Emu Oil Carrier for Antifungal, Antibacterial, and Antiviral Medications | |
| KR20040087006A (en) | Seat-type hydrogel pack using water soluble polymer and the manufacturing process thereof | |
| Ding et al. | Recent advances in burn wound management in China | |
| JPH0344310A (en) | Cosmetic containing zizania latifolia o.stapf and neighbors thereof | |
| JPH0343079A (en) | Enzymic agent | |
| DE3139089A1 (en) | Protein-based sheet-like structures as carriers of therapeutically active, non-immobilised enzymes | |
| RU2115436C1 (en) | Agent for wound treatment | |
| JPH11114049A (en) | Wound coating material | |
| JPH1149660A (en) | Water-activated patch for pimple and its use | |
| JPS63179819A (en) | Skin external preparation containing luffe cylindrica essence for peripheral part of anus | |
| ANDERSON | Tyrothricin in cutaneous infections |